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Abstract
Objective: The objective of this study was to assess the association 
between nonalcoholic fatty liver disease (NAFLD) and cardiovascular risk 
factors.
Materials and Methods: This was a hospital-based, cross-sectional study. 
We retrospectively analyzed the medical records of all the people who 
received periodic health examinations at one medical center in Taichung, 
Taiwan from 2001 to 2004. Subjects with alcoholism and those who were 
positive for hepatitis B surface antigen and hepatitis C virus antibody were 
excluded. In all, 3488 subjects were included for further analysis. The t test, 
χ2 test and multivariate logistic regression were used.
Results: There were 1766 men (50.6%) and 1722 women (49.4%). The 
mean age was 49.4 ± 12.4 years (range, 20–87 years). The overall prevalence 
of NAFLD was 46.9%, with significantly higher prevalence in men than in 
women (55.4% vs. 38.3%, p< 0.001). Multivariate logistic regression analy-
sis showed that the factors that were significantly related to NAFLD were 
male gender (OR, 1.81), generalized obesity (OR, 2.94), central obesity (OR, 
2.12), hyperglycemia (OR, 2.05), hypercholesterolemia (OR, 1.32), hyper-
triglyceridemia (OR, 2.22), high levels of low-density lipoprotein cholesterol 
(OR, 1.29), low levels of high-density lipoprotein cholesterol (OR, 1.53), and 
hyperuricemia (OR, 1.63).
Conclusion: We found that NAFLD is significantly related to cardiovascular 
risk factors and hyperuricemia. [Tzu Chi Med J 2008;20(3):213–217]
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1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is a relatively 
common problem, and is usually incidentally found 
on abdominal sonography during health examinations 
[1–5]. Although the natural course of NAFLD is still 
poorly understood, generally speaking, it is considered 
to be a fairly benign and asymptomatic condition with 
little progression and no risk of mortality [6]. However, 
there are some reports that NAFLD can progress to 
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liver cirrhosis and even liver failure [7–9]. Because 
the liver plays a central role in the metabolism of 
carbohydrates and lipids [10], the association be-
tween NAFLD and metabolic disorders has been 
widely investigated [1–4,10–15]. Metabolic disorders 
are a topic of concern that has been debated often 
and vigorously, and include some of the following: 
obesity, diabetes mellitus, dyslipidemia, essential 
hypertension and hyperuricemia [16–23]. The major-
ity of these disorders are considered to be risk fac-
tors for the development of cardiovascular disease 
[16–23]. Modification of certain major risk factors may 
decrease a patient’s risk of developing cardiovascu-
lar disease and other serious complications [16,17]. 
In 2005, cardiovascular disease was the third leading 
cause of death in Taiwan after neoplasms and cere-
brovascular disease [24]. The relationship between 
NAFLD and cardiovascular risk factors has rarely been 
studied in Taiwan. Therefore, we conducted a study to 
explore the following questions. (1) What is the prev-
alence of NAFLD in Taiwan? (2) What are the related 
factors for NAFLD?
2. Materials and methods
2.1. Study population
This was a hospital-based, cross-sectional study. We 
retrospectively analyzed the medical records of all 
people who received periodic health examinations at 
one medical center located in Taichung, Taiwan from 
2001 to 2004. Subjects who habitually drank alcohol 
and who were positive for hepatitis B surface antigen 
and hepatitis C virus antibody were excluded. In all, 
3488 subjects were included for further analysis. 
The institutional review board of the medical center 
approved this retrospective study.
2.2. Sociodemographic characteristics and 
other related factors
Subjects who had never smoked or had quit smoking 
were defined as nonsmokers. Subjects who currently 
smoked were defined as smokers. Abdominal sonog-
raphy was performed by gastroenterologists using a 
high-resolution real-time machine (Toshiba Sonolayer 
SSA-270A, convex-type 3.5 MHz transducer; Toshiba, 
Tochigi-Ken, Japan). Fatty liver was diagnosed accord-
ing to international criteria [15,25,26].
Venous blood samples were obtained in the morn-
ing after a 12-hour overnight fast. A number of bio-
chemical markers, such as total cholesterol (TC), 
triglycerides (TG), high-density lipoprotein cholesterol 
(HDL-C), fasting glucose and uric acid were measured 
by a biochemical autoanalyzer (Hitachi 736-15; Hitachi 
Corp., Tokyo, Japan) in the clinical laboratory of the 
medical center.
2.3. Diagnostic criteria
Generalized obesity was defined as a body mass 
index (BMI) ≥ 27 kg/m2 [27]. Central obesity was de-
fined as a waist circumference ≥ 90 cm for men or 
≥ 80 cm for women [27]. Hypercholesterolemia was 
defined as total cholesterol ≥ 200 mg/dL [28]. 
Hypertriglyceridemia was defined as TG ≥ 150 mg/dL 
[28]. A low level of HDL-C was defined as < 40 mg/dL 
for men or < 50 mg/dL for women [28]. If TG < 400 mg/
dL, then low-density lipoprotein cholesterol (LDL-C) 
was calculated by the following formula suggested by 
Friedewald et al: LDL-C = TC − (HDL-C + TG/5) [29]. A 
high level of LDL-C was defined as ≥ 130 mg/dL [28]. 
A ratio of TC/HDL-C > 5 was defined as abnormal 
[30]. If subjects had a fasting glucose level ≥ 110 mg/
dL or were receiving drug treatment for elevated glu-
cose, they were considered to have hyperglycemia 
[31]. Subjects were considered to have hypertension 
if their average blood pressure on both hand read-
ings exceeded 140 mmHg systolic and/or 90 mmHg 
diastolic or they were receiving antihypertensive drug 
treatment [32]. Hyperuricemia was defined as serum 
uric acid ≥ 7.0 mg/dL for men and ≥ 6.5 mg/dL for 
women [18].
2.4. Statistical analysis
Statistical analysis was performed using SPSS Taiwan 
version 10.0 (Sinter Information Corp., Taipei, Taiwan). 
The t test, χ2 test and multivariate logistic regression 
were used for statistical analysis. A p value less than 
0.05 was considered statistically significant.
3. Results
3.1. Characteristics of the study population
Among the subjects, there were 1766 men (50.6%) 
and 1722 women (49.4%). The mean age was 
49.4± 12.4 years (range, 20–87 years). The overall 
prevalence of NAFLD was 46.9%, with a significantly 
higher prevalence in men than in women (55.4% vs.
38.3%, p< 0.001) (Fig. 1).
3.2. Univariate analysis of cardiovascular 
risk factors for NAFLD
Using the χ2 test, factors that were found to be sig-
nificantly related to NAFLD were generalized obesity, 
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central obesity, hypertension, hyperglycemia, hyper-
cholesterolemia, hypertriglyceridemia, a high level of 
LDL-C, a low level of HDL-C, a high ratio of TC/HDL-C, 
and hyperuricemia (p< 0.001) (Table 1). Subjects with 
NAFLD were also significantly older as shown by t test 
(p< 0.001).
3.3. Multivariate logistic regression 
analysis of related factors for NAFLD
Only the significantly related factors identified in uni-
variate analysis were further analyzed. In the final 
model, multivariate logistic regression analysis showed 
that the factors that were significantly related to NAFLD 
were male gender, generalized obesity, central obesity, 
hyperglycemia, hypercholesterolemia, hypertriglyceri-
demia, a high level of LDL-C, a low level of HDL-C, and 
hyperuricemia (Table 2).
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Fig. 1 — Prevalence of nonalcoholic fatty liver disease by 
gender.
Table 1 — Association between nonalcoholic fatty liver disease and cardiovascular risk factors by univariate analysis*
Variable Normal Fatty liver p
Age (yr) 47.5 ± 13.0 51.6 ± 11.3 < 0.001
Generalized obesity    < 0.001
  No 1735 (60.5) 1133 (39.5)
  Yes 116 (18.7) 504 (81.3)
Central obesity   < 0.001
  No 1322 (67.5) 636 (32.5)
  Yes 529 (34.6) 1001 (65.4)
Hypertension   < 0.001
  No 1505 (58.2) 1080 (41.8)
  Yes 346 (38.3) 557 (61.7)
Hyperglycemia   < 0.001
  No 1672 (58.3) 1196 (41.7)
  Yes 179 (28.9) 441 (71.1)
Hypercholesterolemia   < 0.001
  No 1071 (61.3) 676 (38.7)
  Yes 780 (44.8) 961 (55.2)
Hypertriglyceridemia   < 0.001
  No 1664 (61.1) 1061 (38.9)
  Yes 187 (24.5) 576 (75.5)
LDL-C ≥ 130 mg/dL   < 0.001
  No 1171 (60.2) 773 (39.8)
  Yes 680 (44.0) 864 (56.0)
Low level of HDL-C    < 0.001
  No 1138 (62.7) 676 (37.3)
  Yes 713 (42.6) 961 (57.4)
TC/HDL-C > 5   < 0.001
  No 1482 (64.1) 829 (35.9)
  Yes 369 (31.4) 808 (68.6)
Hyperuricemia   < 0.001
  No 1495 (60.7) 966 (39.3)
  Yes 356 (34.7) 671 (65.3)
Smoker   0.091
  No 1500 (53.8) 1289 (46.2)
  Yes 351 (50.2) 348 (49.8)
*Data presented as mean ± standard deviation or n (%). LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol; 
TC/HDL-C = ratio of total cholesterol to high-density lipoprotein cholesterol.
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4. Discussion
NAFLD is believed to be one of the most common 
liver diseases in Western countries and has a notably 
high potential for reversibility [1–5,12].
The prevalence of NAFLD was 46.9% in our study. 
Large-scale investigations in Taiwan, India, and Israel 
indicate that the prevalence of NAFLD is around 
11.5–30%, depending on the population studied 
[33–35]. It is possible that the subjects we studied 
were more concerned about their health problem, 
such as fatty liver, and therefore came to the hospital 
for health examination. That led to a higher prevalence 
in our study. Another reason may be that we only ex-
cluded habitual alcohol drinkers. Thus, some heavy 
social drinkers might have been included in this study.
As reported in previous studies, metabolic disorders 
often cluster within the same individual [1–4,10–15]. 
The liver plays a central role in the metabolism of car-
bohydrates, lipids and steroids [10]. The real associa-
tion between NAFLD and metabolic disorders has been 
explored worldwide, but controversy still exists about 
the role of NAFLD [1–4,10–15]. In our study, the factors 
that were significantly related to NAFLD were gener-
alized obesity, central obesity, hyperglycemia, hyper-
cholesterolemia, hypertriglyceridemia, a high level of 
LDL-C, a low level of HDL-C, and hyperuricemia. Brea 
and colleagues [36] suggested that if NAFLD is de-
tected by abdominal ultrasound, clinicians should be 
alert to an increased risk of cardiovascular disease.
The limitations of this study are that it was a retro-
spective hospital-based study, which could introduce 
a sampling bias, and because of the inherent limita-
tions of a cross-sectional study, we could not address 
any substantial causal-effect implications between 
NAFLD and cardiovascular risk factors or hyperuri-
cemia. Therefore, more research is needed to deter-
mine whether NAFLD shares the same pathogenesis 
as cardiovascular risk factors and hyperuricemia, or 
whether NAFLD is another component of the meta-
bolic syndrome.
In conclusion, this study illustrates that NAFLD 
has a significant relationship with cardiovascular risk 
factors and hyperuricemia.
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